A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

Who is this study for? Patients with Bacterial Infections
What treatments are being studied? Dalbavancin
Status: Completed
Location: See all (84) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 17
Healthy Volunteers: f
View:

• Male or female patients birth to 17 years (inclusive)

• A clinical picture compatible with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) suspected or confirmed to be caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA).

• In addition to local signs of ABSSSI, the patient has at least one of the following:

• Fever, defined as body temperature ≥ 38.4°C (101.2°F) taken orally, ≥ 38.7°C (101.6°F) tympanically, or ≥ 39°C (102.2°F) rectally (core temperature) OR

• Leukocytosis (WBC \> 10,000 mm3) or leukopenia (WBC \< 2,000 mm3) or left shift of \>10% band neutrophils

• Infection either involving deeper soft tissue or requiring significant surgical intervention

• Major cutaneous abscess characterized as a collection of pus within the dermis or deeper that is accompanied by erythema, edema and/or induration which i. requires surgical incision and drainage, and ii. is associated with cellulitis such that the total affected area involves at least 35 cm2 of erythema, or total affected area of erythema is at least BSA (m2) x 43.0 (cm2/m2), OR iii. alternatively, involves the central face and is associated with an area of erythema of at least 15 cm2 b. Surgical site or traumatic wound infection characterized by purulent drainage with surrounding erythema, edema and/or induration which occurred within 30 days after the trauma or surgery and is associated with cellulitis such that: i. the total affected area involves at least 35 cm2 of erythema, or total affected area of erythema is at least BSA (m2) x 43.0 (cm2/m2), OR ii. alternatively, involves the central face and is associated with an affected area of at least 15 cm2 c. Cellulitis, defined as a diffuse skin infection characterized by spreading areas of erythema, edema and/or induration and: i. is associated with erythema that involves at least 35 cm2 of surface area, or surface area of erythema is at least BSA (m2) x 43.0 (cm2/m2), OR ii. alternatively, cellulitis of the central face that is associated with an affected area of at least 15 cm2 5. In addition to the requirement for erythema, all patients are required to have at least two (2) of the following signs of ABSSSI: a. Purulent drainage/discharge b. Fluctuance c. Heat/localized warmth d. Tenderness to palpation e. Swelling/induration

⁃ In patients age birth to \< 3 months, each patient must meet the following inclusion criteria to be enrolled in this study.

∙ Male or female patients from birth to \< 3 months of age, including pre-term neonates (gestational age ≥ 32 weeks)

‣ A clinical picture compatible with an ABSSSI suspected or confirmed to be caused by Gram-positive bacteria, including MRSA.

∙ OR

∙ Suspected or confirmed sepsis including any of the following clinical criteria:

• Hypothermia (\<36°C) OR fever (\>38.5°C)

• Bradycardia OR tachycardia OR rhythm instability

• Hypotension OR mottled skin OR impaired peripheral perfusion

• Petechial rash

• New onset or worsening of apnea episodes OR tachypnea episodes OR increased oxygen requirements OR requirement for ventilation support

• Feeding intolerance OR poor sucking OR abdominal distension

• Irritability

• Lethargy

• Hypotonia

‣ In addition, patients must meet at least one of the following laboratory criteria:

∙ a. White blood cell count ≤4.0 × 10\^9/L OR ≥20.0 × 10\^9/L b, Immature to total neutrophil ratio \>0.2 c. Platelet count ≤100 × 10\^9/L d. C-reactive protein (CRP) \>15 mg/L OR procalcitonin ≥ 2 ng/mL e. Hyperglycemia OR Hypoglycemia f. Metabolic acidosis

‣ Infections must be of sufficient severity to merit hospitalization and parenteral antibiotic therapy. These infections may include:

⁃ Cutaneous or subcutaneous abscess

• Surgical site or traumatic wound infection

• Cellulitis, Erysipelas

• Omphalitis

• Impetigo and bullous impetigo

• Pustular folliculitis

• Scarlet fever

• Staphylococcal scalded skin syndrome

• Streptococcal toxic shock syndrome

⁃ Erythematous based-erosion

⁃ Other infections originating in the skin or subcutaneous tissue and associated with signs and symptoms of sepsis as defined in Inclusion Criterion 2.

‣ Patients must be expected to survive with appropriate antibiotic therapy and appropriate supportive care throughout the study.

Locations
United States
Alabama
University of South Alabama /ID# 237446
Mobile
Arizona
Valleywise Health Medical Center /ID# 234343
Phoenix
California
Southbay Pharma Research /ID# 235700
La Palma
University of California, Los Angeles /ID# 237533
Los Angeles
Colorado
Duplicate_Children's Hospital Colorado /ID# 237622
Aurora
Florida
Global Research Holdings LLC /ID# 235747
Panama City
Tampa General Hospital /ID# 237061
Tampa
Georgia
Children's Healthcare of Atlanta - Ferry Rd /ID# 237003
Atlanta
Maryland
University of Maryland Medical Center /ID# 234353
Baltimore
Missouri
Duplicate_Children's Mercy Hospital and Clinics /ID# 237800
Kansas City
North Carolina
Duke University Medical Center /ID# 234315
Durham
New Jersey
Robert Wood Johnson Univ Hosp /ID# 237862
New Brunswick
New York
NYU School of Medicine /ID# 236783
New York
SUNY Upstate Medical University /ID# 236831
Syracuse
Ohio
Cleveland Clinic Main Campus /ID# 237564
Cleveland
Other Locations
Argentina
Hospital de Ninos Dr. Orlando Alassia /ID# 235562
Santa Fe
Belarus
Grodno Regional Infectious Disease Hospital /ID# 235661
Grodno
Mogilev Regional Children's Hospital /ID# 235657
Mogilev
Vitebsk Regional Clinical Center for Children /ID# 235659
Vitebsk
Brazil
Duplicate_Hospital Pequeno Princípe /ID# 235629
Curitiba
Duplicate_Irmandade Santa Casa de Misericórdia de Porto Alegre /ID# 235627
Porto Alegre
Bulgaria
University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965
Bulgas
MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539
Kozloduy
UMHAT Dr Georgi Stranski EAD /ID# 237829
Pleven
UMHAT Dr Georgi Stranski EAD /ID# 237830
Pleven
Multiprofile Hospital for Active Treatment ( UMHAT) Sveti Georgi EAD Plovdiv /ID# 235487
Plovdiv
UMHAT Sveti Georgi /ID# 237026
Plovdiv
UMHAT Kanev /ID# 237809
Rousse
Medical center 1 Sevlievo /ID# 237470
Sevlievo
MHATEM N.I.Pirogov Septic Surgery Clinic /ID# 235541
Sofia
SHAT Hematologic Diseases /ID# 237915
Sofia
University Multiprofile Hospital for Active Treatment Prof. Dr. Stoyan Kirkovich /ID# 235543
Stara Zagora
Chile
Hospital de Ninos Dr. Roberto del Rio /ID# 235568
Independencia
Hospital El Carmen de Maipú /ID# 235570
Santiago
Colombia
Fundacion Cardioinfantil /Id# 238041
Bogota
Unidad De Investigacion Clinica Universidad De La Sabana /ID# 235566
Chía
Hospital Universitario San Vic /ID# 238117
Medellín
Georgia
LTD Unimedi Kakheti Batumi Maternal and Child Healthcare Center /ID# 235643
Batumi
LEPL Tbilisi State Medical University Givi Zhvania Academic Clinic of Pediatry /ID# 235645
Tbilisi
LTD M. Iashvili Children's Central Hospital /ID# 235639
Tbilisi
LTD Unimedi Kakheti Children New Hospital /ID# 235634
Tbilisi
Greece
Childrens Hospital of Penteli /ID# 235667
Athens
University General Hospital Attikon /ID# 237398
Athens
Papageorgiou General Hospital Thessaloniki /ID# 237505
Stavroupoli (thessalonikis)
General Hospital of Thessaloniki Hippokrateio /ID# 237186
Thessaloniki
Guatemala
Hospital del Centro Medico Infectology Department /ID# 235522
Guatemala City
Hospital Roosevelt /ID# 235520
Guatemala City
Hospital Valle del Sol /ID# 235569
Guatemala City
Latvia
Daugavpils Regional Hospital /ID# 237022
Daugavpils
Liepaja Regional Hospital /ID# 235650
Liepāja
University Childrens Hospital /ID# 235648
Riga
Lithuania
Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 236947
Kaunas
Klaipeda Children's Hospital /ID# 235652
Klaipėda
Duplicate_Children's Hospital Affiliate - Vilnius University Hospital Santariski /ID# 235654
Vilnius
Mexico
Instituto Nacional de Pediatria /ID# 235506
Coyoacán
Hospital General Dr. Agustin O'Horan /ID# 235510
Mérida
Hospital Infantil de Mexico Federico Gomez /ID# 235508
Mexico City
Hospital Universitario Dr. Jose Eleuterio Gonzalez /ID# 237597
Monterrey
Panama
Hospital Materno Infantil José Domingo de Obaldía /ID# 235625
Chiriquí
Hospital Del Niño Dr. José Renán Esquivel /ID# 235572
Panama City
Poland
Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza /ID# 236920
Bydgoszcz
Specjalistyczny ZOZ nad Matka i Dzieckiem w Poznaniu Oddzial Obserwacyjno /ID# 235518
Poznan
Panstwowy Instytut Medyczny MSWiA w Warszawie /ID# 237112
Warsaw
Romania
Spitalul Clinic de Boli infectioase si Tropicale Dr. Victor Babes /ID# 235610
Bucharest
Institutul National de Boli Infectioase Prof. Dr. Matei Bals /ID# 235606
Sector 2
Spitalul Clinic Judeatean Mures /ID# 234728
Târgu Mureş
Spitalul Clinic de Urgenta pentru Copii ?Louis Turcanu? /ID# 235608
Timișoara
Russian Federation
Smolensk State Medical University /ID# 236996
Smolensk
Stavropol State Medical University /ID# 236239
Stavropol
Regional Childrens Hospital /ID# 235560
Vologda
South Africa
Peermed Clinical Trial Centre /ID# 235514
Kempton Park
Mzansi Ethical Research Center /ID# 236480
Middelburg
Spain
Hospital Donostia /ID# 237773
Donostia / San Sebastian
Hospital Sant Joan de Deu /ID# 236797
Esplugues De Llobregat
Hospital General Universitario Gregorio Maranon /ID# 236955
Madrid
Hospital Universitario La Paz /ID# 237775
Madrid
Complejo Hospitalario Universitario de Santiago /ID# 235512
Santiago De Compostela
Hospital Universitario y Politecnico La Fe /ID# 237086
Valencia
Ukraine
Dnipropetrovsk Regional children's Clinical Hospital /ID# 235558
Dnipro
Ivano-Frankivsk Pediatric Regional Clinical Hospital /ID# 235556
Ivano-frankivsk
PE PMC Acinus, Medical and Diagnostic Center /ID# 237514
Kropyvnytskyi
Lviv Regional Clinical Hospital /ID# 236921
Lviv
Ukrainian Medical Stomatological Academy - Children's City Clinical Hospital /ID# 234886
Poltava
Communal Nonprofit Enterprise Central City Clinical Hospital of Uzhhorod City /ID# 238058
Uzhhorod
Time Frame
Start Date: 2017-03-30
Completion Date: 2024-01-01
Participants
Target number of participants: 199
Treatments
Experimental: Dalbavancin single-dose
Participants received dalbavancin administered intravenously as follows: birth to \< 3 months old and 3 months to \< 6 years old: 22.5 mg/kg (maximum 1500 mg) on Day 1; ≥6 years to 17 years old (inclusive): 18 mg/kg (maximum 1500 mg) on Day 1. Participants aged birth to \< 3 months were not randomized; all received dalbavancin single-dose.
Experimental: Dalbavancin two-dose
Participants received dalbavancin administered intravenously as follows: 3 months to \< 6 years old: 15 mg/kg (maximum 1000 mg) on Day 1, and 7.5 mg/kg (maximum 500 mg) on Day 8; ≥6 years to 17 years old (inclusive): 12 mg/kg (maximum 1000 mg) on Day 1, and 6 mg/kg (maximum 500 mg) on Day 8.
Active_comparator: Comparator
Participants 3 mos to \< 6 yrs old and ≥6 yrs to 17 yrs old received a 10-14 day course of either vancomycin 10 to 15 mg/kg/dose, not to exceed a 4000 mg total daily dose; or oxacillin 30 mg/kg/dose, infused over 60 (± 10) mins every 6 (± 1) hrs; or flucloxacillin 50 mg/kg/dose, infused over 60 (± 10) mins every 6 (± 1) hrs, not to exceed a 2000 mg total daily dose. Vancomycin was to be taken for methicillin-resistant Gram-positive infections. Based on local practice patterns/approvals for clinical use in the pediatric population, oxacillin or flucloxacillin were supplied as an IV comparator. At investigator's discretion, after 72 hrs of IV therapy, those on oxacillin or flucloxacillin could switch to oral cefadroxil (dose for infants/children: 15 mg/kg/dose every 12 hrs, max 2 g/day; dose for adolescents: 500-1000 mg every 12 hrs), and if infection with methicillin-resistant S. aureus was confirmed, those on vancomycin were allowed to switch to oral clindamycin 10 mg/kg every 8 hrs.
Sponsors
Leads: AbbVie

This content was sourced from clinicaltrials.gov